2022 March Life Sciences Update

Contents

Summary

Summary

02

Funding Remains Strong

03

The life sciences industry has been on the rise over the past half-decade thanks to a surge in new products and technology, as well as an influx of capital from both public and private investors. The last two years, in particular, have seen tremendous growth with $70 billion of private equity (PE) capital and public National Institutes of Health (NIH) funding pouring into life sciences-related companies in North America in 2020 and a record $78 billion in 2021. Building off the momentum of last year’s successful implementation of the mRNA technology, opening the door to new treatments for diseases like cystic fibrosis, cancer and HIV, the industry is poised for another successful year in 2022.

This 2022 Q1 U.S. Life Sciences Update breaks down the current trends in the life sciences industry at a high level by exploring: 1. Where the capital is flowing; 2. Where the talent can be found; and 3. The impact on the lab space market (i.e., demand, cost and new construction). The report also contains a market-by market analysis that provides detailed overviews of some of the largest life sciences markets in the U.S.

Talent is on the Rise

07

Sector Growth = Increased Demand for Lab Space Market-by-Market Analysis

09

12

Boston

13

New Jersey

14

New York City

15

Philadelphia

16

Raleigh / Durham

17

San Diego

18

San Francisco Bay Area

19

Suburban Maryland (I-270 Corridor)

20

Appendix

21

2 / CUSHMAN & WAKEFIELD

LIFE SCIENCES 2022 MARCH UPDATE